Objectives: To analyze long-term oncological outcome along with prognostic risk factors
in a large cohort of patients with colorectal liver metastases (CRLM) undergoing ALPPS.
Background: ALPPS is a two-stage hepatectomy variant that increases resection rates
and R0 resection rates in patients with primarily unresectable CRLM as evidenced in
a recent randomized controlled trial. Long-term oncologic results, however, are lacking.
Methods: Cases in- and outside the International ALPPSRegistry were collected and
completed by direct contacts to ALPPS centers to secure a comprehensive cohort. Overall,
cancer-specific (CSS), and recurrence-free (RFS) survivals were analyzed along with
independent risk factors using Cox-regression analysis. Results: The cohort included
510 patients from 22 ALPPS centers over a 10year period. Ninety-day mortality was
4.9% and median overall survival, CSS, and RFS were 39, 42, and 15 months, respectively.
The median follow-up time was 38 months (95% confidence interval 32-43 months). Multivariate
analysis identified tumor-characteristics (primary T4, right colon), biological features
(K/N-RAS status), and response to chemotherapy (Response Evaluation Criteria in Solid
Tumors) as independent predictors of CSS. Traditional factors such as size of metastases,
uni versus bilobar involvement, and liverfirst approach were not predictive. When
hepatic recurrences after ALPPS was amenable to surgical/ablative treatment, median
CSS was significantly superior compared to chemotherapy alone (56 vs 30 months, P
< 0.001). Conclusions: This large cohort provides the first evidence that patients
with primarily unresectable CRLM treated by ALPPS have not only low perioperative
mortality, but achieve appealing long-term oncologic outcome especially those with
favorable tumor biology and good response to chemotherapy.
